This is the new MLex platform. Existing customers should continue to access MLex here until migrated to the new platform. For any migration queries, please contact Customer Services or your Account Manager.

Teva fine sees EU break new antitrust ground on patents, disparagement

By Lewis Crofts ( October 31, 2024, 17:08 GMT | Comment) -- Corporate boardrooms will take note of today’s eye-watering fine of 462.6 million euros ($500 million) imposed on Teva for abusing the market for a multiple sclerosis treatment, but it is the legal innovations of the decision that may have the longer-lasting impact....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections